Skip to main content

Table 1 Basic characteristics of all eligible studies (n = 35)

From: Network meta-analysis of triazole, polyene, and echinocandin antifungal agents in invasive fungal infection prophylaxis in patients with hematological malignancies

Study Country Design Sample size Age (year) Follow-up Treatment regimes
Group 1 Group 2 Group 3
Cornely 2007 Germany Multicenter 602 (304 vs 240 vs 58) (49 ± 17) vs (50 ± 17) vs (52 ± 14) 100 days Posaconazole 200 mg, oral suspension, thrice daily Fluconazole 400 mg, oral suspension, once daily Itraconazole 200 mg, oral solution, twice daily
Cornely 2017 Germany Multicenter 355 (237 vs 118) 45 (32–57) vs 47 (28–60) 30 days Amphotericin B 5 mg/kg i.v. Placebo n.a.
Epstein 2018 US Single center 113 (58 vs 55) 61 (32–75) vs 59 (26–74) 12 weeks Micafungin 100 mg i.v. daily Posaconazole 400 mg, oral suspension, twice daily n.a.
Fisher 2019 US Multicenter 510 (254 vs 256) 10 (0–26) vs 9 (0–21) n.r. Caspofungin 70 mg/m2 i.v. per day Fluconazole 6 mg or 12 mg/kg i.v. or oral once daily n.a.
Mandhaniya 2011 India Single center 100 (50 vs 50) 5.5 (1.5–15) vs 9 (2–15) 7 days Voriconazole 6 mg/kg/ to 4 mg/kg twice daily Amphotericin B 0.5 mg/kg i.v thrice weekly n.a.
Mattiuzzi 2003 US Single -center 137 (70 vs 67) 64 (36–83) vs 57 (19–84) 23.3–23.6 months Amphotericin B 3 mg/kg i.v. per week Fluconazole capsules 200 mg every 12 h n.a.
Mattiuzzi 2006 US Single center 192 (86 vs 106) 60 (17–82) vs 64 (22–82) n.r. Itraconazole 200 mg i.v. once daily Caspofungin 50 mg i.v. once daily n.a.
Mattiuzzi 2011 US Single center 123 (71 vs 52) 59 (23–83) vs 60 (21–80) n.r. Voriconazole 400 mg every 12 h, followed by 300 mg i.v. twice daily Itraconazole 200 mg twice daily for 2 days, followed by 200 mg i.v. daily n.a.
Shen 2013 China Multicenter 234 (117 vs 117) 40 (17–61) vs 40 (15–68) 100 days Posaconazole 200 mg, oral suspension, thrice daily Fluconazole 400 mg once daily n.a.
Vehreschild 2007 Germany Multicenter 25 (10 vs 15) 53 (18–73) vs 54 (26–71) 28 days Voriconazole 200 mg Placebo n.a.
Winston 1993 US Multicenter 256 (124 vs 132) 42.5 (17–82) vs 44.4 (17–73) 90 days Fluconazole 400 mg once daily Placebo twice daily n.a.
Chaftari 2012 US Single center 40 (19 vs 21) 56 (21–69) vs 55 (20–66) 3 weeks Amphotericin B 7.5 mg/kg once per week Posaconazole 200 mg, oral suspension, thrice daily n.a.
Ellis 1995 Germany Single center 41 (16 vs 25) (26.2 ± 13.5) vs (23.6 ± 10.9) 100 days Fluconazole 8 mg/(kg · day), followed by 4 mg/(kg · day) i.v. Amphotericin B 1 mg/(kg · day), followed by 0.5 mg/(kg · day) n.a.
Harousseau 2000 Belgium Multicenter 557 (281 vs 276) 48 (15–75) vs 49.5 (17–82) 56 days Itraconazole solution 2.5 mg/(kg · day) Amphotericin B capsules 500 mg, 4 times/day n.a.
Laverdiere 2000 Canada Single center 266 (135 vs 131) 47.6 (18–80) vs 45 (17–77) n.r. Fluconazole 400 mg once daily Placebo once daily n.a.
Oren 2006 Israel Single center 195 (99 vs 96) 49 (18–73) vs 50 (17–75) 3 months Fluconazole 400 mg i.v. or oral daily Itraconazole 200 mg oral daily, twice daily or 200 mg i.v. daily n.a.
Rotstein 1999 Canada Single center 274 (141 vs 133) 47.6 (18–80) vs 45.2 (17–77 n.r. Fluconazole 400 mg/day Placebo n.a.
Slavin 1995 Australia Single center 300 (152 vs 148) 6.5 (13–60) vs 36.2 (13–65) 110 days Fluconazole 400 mg/day Placebo n.a.
Wingard 2010 US Multicenter 600 (305 vs 295) 43 (2.7–65.7) vs 43 (9–65) 100 days Voriconazole 200 mg twice daily Fluconazole 400 mg per day n.a.
Annaloro 1995 Italy Single center 59 (31 vs 28) 30 (17–53) vs 38 (13–56) n.r. Itraconazole 400 mg per day Fluconazole 300 mg per day n.a.
Chandrasekar 1994 US Single center 46 (23 vs 23) 39 (17–77) vs 37 (19–67) 70 days Fluconazole 400 mg per day Placebo n.a.
Glasmacher 2006 Germany Multicenter 494 (248 vs 246) n.a. n.r. Itraconazole oral solution 5 mg/kg Fluconazole oral solution 400 mg n.a.
Ito 2007 Japan Multicenter 209 (103 vs 106) 58 (16–80) vs 53 (16–80) n.r. Itraconazole oral capsules 200 mg/day Fluconazole oral capsules 200 mg/day n.a.
Marks 2011 UK Multicenter 489 (224 vs 231) 43.3 (11–70) vs 42.3 (13–70) 28 days Voriconazole 6 mg i.v., followed by 200 mg Itraconazole 200 mg, followed by solution 200 mg n.a.
Marr 2004 US Single center 299 (148 vs 151) n.a. 23.3–23.6 months Fluconazole 400 mg/day, oral or intravenous Itraconazole oral solution 2.5 mg/kg, thrice daily or intravenous infusion 200 mg per day n.a.
Menichetti 1999 Italy Multicenter 405 (201 vs 204) 44 (17–79) vs 44 (17–75) n.r. Itraconazole, oral solution, 2.5 mg/kg, 2 times/day Placebo n.a.
Nucci 2000 Brazil Multicenter 210 (104 vs 106) 25.5 (5–63) vs 30 (6–67) 39 days Itraconazole capsules 100 mg Placebo n.a.
Schaffner 1995 Switzerland Single-center 151 (75 vs 76) 40 (17–71) vs 39 (17–67) n.r. Fluconazole oral capsule 400 mg Placebo n.a.
Winston 2003 US Multicenter 38 (71 vs 67) 41 (14–63) vs 38 (17–61) 180 days Itraconazole 200 mg/12 h for 2 days i.v., followed by i.v. 200 mg/24 h or 200 mg oral solution/12 h Fluconazole 400 mg intravenously or orally every 24 h n.a.
Yamac 1995 Turkey Single center 70 (41 vs 29) 49 (17–68) vs 50 (16–67) n.r. Fluconazole oral 400 mg Placebo n.a.
Gloria 2012 US Single center 112 (72 vs 40) 60 (19–84) 42 days Amphotericin B 3 mg/kg thrice weekly or 9 mg/kg once weekly i.v. Voriconazole 400 mg, twice daily, followed by 200 mg n.a.
Mike 2015 UK Multicenter 355 (237 vs 118) (44.5 ± 15.16) vs (44.8 ± 17.52) n.r. Amphotericin B 5 mg/kg, twice daily Placebo n.a.
Karthaus 2000 Germany Single center 51 (20 vs 31) 42.5 (19–72) vs 46.0 (22–76) n.r. Amphotericin B 1 mg/kg i.v. over 4 h every 48 h Placebo n.a.
Park 2000 South Korea Single center 250 (165 vs 85) 46 (20–63) vs 50 (20–64) 100 days Micafungin 50 mg/day i.v. as a 1-h infusion Fluconazole oral 400 mg/day n.a.
Wolff 2000 US Multicenter 355 (196 vs 159) 43 (20–68) vs 42 (18–59) n.r. Fluconazole 400 mg/day oral or i.v. Amphotericin B 0.2 mg/kg with a maximum dose of 20 mg i.v. per day n.a.
  1. n.a. Not applicable, n.r. not reported